Cargando…
The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers
SIMPLE SUMMARY: Tumor heterogeneity, drug resistance, and systemic toxicity are major concerns throughout treatments of gynecological cancers. Off-target toxicity is also a significant issue with traditional cancer medicines, preventing patients’ cancers from being adequately treated with chemothera...
Autores principales: | Currie, Jean-Christophe, Demeule, Michel, Charfi, Cyndia, Zgheib, Alain, Larocque, Alain, Danalache, Bogdan Alexandru, Ouanouki, Amira, Béliveau, Richard, Marsolais, Christian, Annabi, Borhane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031804/ https://www.ncbi.nlm.nih.gov/pubmed/35454785 http://dx.doi.org/10.3390/cancers14081877 |
Ejemplares similares
-
TH1902, a new docetaxel‐peptide conjugate for the treatment of sortilin‐positive triple‐negative breast cancer
por: Demeule, Michel, et al.
Publicado: (2021) -
The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells
por: Demeule, Michel, et al.
Publicado: (2022) -
New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells
por: Charfi, Cyndia, et al.
Publicado: (2021) -
A Role for the Cavin-3/Matrix Metalloproteinase-9 Signaling Axis in the Regulation of PMA-Activated Human HT1080 Fibrosarcoma Cell Neoplastic Phenotype
por: Toufaily, Chirine, et al.
Publicado: (2014) -
Periostin, a signal transduction intermediate in TGF-β-induced EMT in U-87MG human glioblastoma cells, and its inhibition by anthocyanidins
por: Ouanouki, Amira, et al.
Publicado: (2018)